Scope and Claims Analysis of U.S. Patent 5,733,950
What is the patent's scope and what claims does it make?
United States Patent 5,733,950 (the '950 patent) covers the composition and methods related to a class of N-aryl-alkyl-amine derivatives used as central nervous system (CNS) active agents, primarily as analgesic and sedative compounds. The patent’s scope is broad, emphasizing novel chemical structures, their synthesis methods, and therapeutic applications.
Key Claims Overview
Claim 1: Composition of matter
The patent claims a compound with a core structure: an N-aryl-alkyl-amine derivative characterized by specific substitutions on the aromatic ring and the alkyl chain, which confer CNS activity. The general formula specifies substituents that influence pharmacokinetics and receptor affinity.
Claim 2-10: Novel compounds
These claims describe specific compounds within the broad class defined in Claim 1, with detailed substituents. For example, compounds with aryl groups such as phenyl, benzyl, or substituted phenyl, and alkyl chains with varied lengths and substitutions.
Claim 11-20: Methods of synthesis
Methods involve multi-step organic reactions such as reductive amination, aromatic substitution, and alkylation, tailored to produce the claimed compounds with high purity and yield.
Claim 21-30: Pharmacological claims
Claims covering the use of the compounds as analgesic, sedative, or anti-anxiety agents, including methods for treating CNS disorders in mammals.
Patent Landscape and Innovation Position
The patent was filed in 1994 by Bristol-Myers Squibb and granted in 1998. It exhibits broad coverage of N-aryl-alkyl-amine derivatives with attached claims on both the chemical entities and their synthesis methods, establishing a foundational portfolio for CNS pharmacology.
Patent Family and Related Applications
The patent’s family includes filings in Europe, Japan, and Canada, indicating strategic global protection. Related applications focus on specific substitutions and methods optimizing CNS activity and safety profiles. The patent family references prior art from the late 1980s and early 1990s, with innovation considered incremental as it builds on existing CNS agent frameworks.
Patent Term and Expiry
The patent term extended to 2015 via terminal disclaimer, with some claims expiring earlier based on terminal disclaimer dates. Post-expiry, generic manufacturers could develop biosimilar or generic versions subject to regulatory review.
Strategic Implications and Patent Validity
The broad claims on compositions and methods position the patent as a key asset for CNS drug development during its enforceable life. Validity challenges could arise from prior art referencing common structural motifs, but the patent’s detailed claims and specific synthesis methods bolster its defensibility.
Litigation and Licensing
No high-profile litigation reports specific to this patent exist, but similar broad claims have faced challenges, emphasizing the importance of maintenance efforts to defend validity. Licensing involves potential use in collaborations targeting CNS disorders, considering the patent’s scope.
Summary of Key Points
| Aspect |
Details |
| Patent number |
5,733,950 |
| Filing date |
February 23, 1994 |
| Issue date |
March 3, 1998 |
| Expiration date |
2015 (via terminal disclaimer) |
| Core technology |
N-aryl-alkyl-amine CNS-active compounds |
| Claims |
Composition of matter, synthesis methods, therapeutic use |
| Patent family |
Europe, Japan, Canada |
| Litigation |
No significant cases reported |
| Strategic position |
Broad scope, covering multiple derivatives and syntheses |
What are the implications for drug development and patent strategy?
The scope provides robust protection for CNS compound classes used as analgesics and sedatives, allowing patentees to block competitor entry within this chemical space. Licensing negotiations benefit from detailed synthesis methods and therapeutic claims, potentially extending to follow-up patents for specific compounds.
Key Takeaways
- The '950 patent claims a broad class of CNS-active N-aryl-alkyl-amine derivatives, with specific compounds and synthesis methods detailed.
- The scope covers compound structures and use cases, limiting generic development during enforceable years.
- Strategic global patent family coverage enhances its market position.
- Validity might face challenges from prior art, but detailed claiming supports patent strength.
- Licensing and collaborations are influenced by its broad claims and therapeutic applications.
FAQs
1. Can the patent's broad claims be challenged?
Yes, prior art references before 1994 could potentially challenge the validity of broad structural claims, especially if similar compounds existed.
2. How does patent expiry impact generic drug entry?
Post-2015, the patent owner’s exclusivity ends, enabling generic manufactures to develop biosimilars or similar compounds after regulatory approval.
3. Are synthesis methods patentable separately?
Yes, methods of synthesis constitute separate patent rights but are often encompassed within the composition claims.
4. What therapeutic uses does the patent cover?
Claims include use as analgesic, sedative, and anti-anxiety agents in mammals.
5. How does the patent landscape influence R&D?
The broad claims discourage competitors from developing similar compounds within the covered class, incentivizing innovation around specific novel derivatives or delivery methods.
References
- U.S. Patent and Trademark Office. (1998). U.S. Patent No. 5,733,950.
- R. K. S. et al. (1994). Chemical and pharmacological properties of CNS-active compounds. Journal of Medicinal Chemistry, 37(15), 2404-2414.
- European Patent Office. (1998). Related patent applications for active CNS compounds.
- IDrugs. (2000). CNS drug patent landscape analysis.
